

## Summary of minutes of EUCAST Steering Committee Meeting Rome, Italy, 20-21 November 2006

### Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Canton	RC	Clinical Data Co-ordinator	Spain
Prof Waleria Hryniewicz	WH	EUCAST	Poland
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	CJ-S	SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway
Prof Pietro Varaldo	PV	EUCAST	Italy

### Apologies

Prof Inga Odenholt	IO	SRGA	Sweden
Dr Fred Goldstein	FG	SFM	France

<b>1</b>	<b>Chairman's welcome</b>
<b>2</b>	<b>Minutes of meeting of 11-12 September 2006</b> With other minor corrections the minutes were accepted as a correct record.
<b>3</b>	<p><b>Matters arising from minutes of 11-12 September 2006</b></p> <p>MIC data for <math>\beta</math>-lactam inhibitor combinations with viridans streptococci are being collected.</p> <p>Exception notes for cefuroxime have been provided by DIN and NWGA.</p> <p>A summary of current indications will be included in rationale documents for older penicillins.</p> <p>A table of Monte Carlo simulation data will be included in the cephalosporin technical note.</p> <p>MLS MIC distributions are required, particularly for <i>H. influenzae</i> and staphylococci.</p> <p>Additional penicillin MIC distributions have been provided.</p> <p>Declarations of interest are to be provided by Steering Committee members.</p> <p>Preprints of tigecycline and linezolid technical notes in CMI have been received.</p> <p>Noted MICs of fluoroquinolones commonly 2-3 dilutions higher for <i>E. faecium</i> than <i>E. faecalis</i>.</p> <p>There was discussion on use of piperacillin-tazobactam for <i>S. pneumoniae</i> infections.</p> <p>Re-drafted penicillin breakpoint tables have been sent for comment by National Committees.</p> <p>Management of preparation of rationale documents and technical notes has been taken over by RC as Clinical Data Coordinator.</p> <p>Company versions of rationale documents will be invited when setting breakpoints for new agents.</p> <p>EUCAST suggestions have been sent to ESGARAB on appropriate agents for surveillance.</p> <p>It is not yet clear how the breakpoint error in the tigecycline SPC will be corrected.</p>

- 4 Website**  
No errors or problems have been reported following revision of EUCAST website. All sections and documents will be dated and links to templates and example documents have been added for companies. All documents will be in English. Future developments were discussed.
- 5 Report on EMEA-EUCAST review meeting**  
Reported that at the review meeting it was agreed that the SOP for setting breakpoints will be made more specific; SPCs for new drugs will be sent to EUCAST for proof reading; revision of EUCAST breakpoints may be prompted by any of the company, EUCAST or EMEA; EUCAST harmonised breakpoints could be included in old SPCs when they are revised; for topical agents systemic breakpoints should be used if available, epidemiological cut-offs if not; the case for antifungal breakpoints should be made to the EMEA Specialist Advisory Group.
- 6 Additional national representatives to receive EUCAST documents**  
Agreed that nominated national committee persons would receive minutes, etc as appropriate.
- 7 New quinolone**  
There was further discussion of breakpoints.
- 8 New drugs**  
Current status was reviewed.
- 9 Technical notes and rationale documents**  
Documents for fluoroquinolones, aminoglycosides, carbapenems, glycopeptides, macrolides, penicillins, cephalosporins, tetracyclines and miscellaneous agents are at various stages of completion.
- 10 Expert rules sub-committee**  
There is good progress on rules tables for most groups of agents.
- 11 Breakpoints in Serbia**  
A national workshop has agreed to use EUCAST breakpoints for MICs.
- 12 ECDC**  
GK and DB have been formally interviewed regarding ECDC taking over funding of EUCAST. Outcome is unlikely to be heard before March 2007.
- 13 Fluconazole rationale document**  
Following wide consultation there was discussion of the document and modifications will be proposed.
- 14 Macrolides**  
Draft macrolide breakpoint tables were reviewed and national committees will be asked for comments.
- 15 ISO/CEN**  
The international standard broth microdilution MIC method has gone to print. The document on assessment of in-vitro methods will go for final voting following update.
- 16 Miscellaneous agents**  
Data collection has started for miscellaneous agents where breakpoints are not yet harmonised.
- 17 Penicillins**  
Comments are awaited from national committees and draft breakpoints will be discussed at the next meeting.
- 18 Any other business**  
Suggested changes to definitions of breakpoints and epidemiological cut-offs were not

accepted.

There will be a joint meeting with the Antifungal Susceptibility Testing Subcommittee at the next Steering Committee meeting.

The possibility of developing EUCAST breakpoints for a CLSI-type disc diffusion technique was positively discussed but the work involved was recognised.

**19**

**Next meetings**

29-30 January 2007, Madrid

3-4 April 2007, Munich (at ECCMID)

14-15 June 2007, Copenhagen

6-7 September 2007. Berlin

19-20 November 2007. Venue to be agreed.

Ratified summary of minutes of meeting 20-21 November 2006.